Friday, June 15, 2007

“Next Generation” ViziLite Plus and Management Shake Up


Lots of changes at Zila both in product and management...


Phoenix, AZ – ViziLite® Plus with TBlue630, the emerging standard of care for the early detection of oral abnormalities that could lead to cancer, now includes Pearlescent™ retractors, replacing the earlier transparent devices. With an opaque backside, the new retractors focus more light on the oral cavity, and block light from shining directly back at the clinician.

“Dentists are having considerable success with ViziLite Plus,” said David Barshis, vice president and general manager of Zila Pharmaceuticals. “We are delighted to respond to their feedback with our new Pearlescent retractor, advancing this exciting, effective technology.”

Scottsdale, Arizona, dentist Paul Douglas has been using ViziLite Plus extensively. “My patients really appreciate the ViziLite Plus exam,” he said. “I provide it as part of nearly all routine annual exams. On several occasions, ViziLite helped identify areas of concern that otherwise would have been difficult, if not impossible, to find.”

ViziLite Plus is available from Pro-Dentec sales representatives and Zila Pharmaceuticals customer service representatives. Information is available at www.ViziLite.com, or 800-922-7887.

PHOENIX--(BUSINESS WIRE)--June 14, 2007--Zila, Inc. (NASDAQ GM: ZILA), announced today that Douglas Burkett has resigned as CEO and director of Zila, effectively immediately, in order to pursue other interests.

Frank J. Bellizzi, D.M.D., Zila Executive Vice President and the President of its pharmaceutical division, will expand his leadership responsibilities while the Board addresses the CEO position. David R. Bethune, Chairman of the Board of Zila commented, "I have great confidence in Frank's ability and look forward to working closely with him as we move forward."

Mr. Bellizzi stated, "As an organization, we intend to aggressively drive the Company to profitability and continue to expand Zila's leadership position in oral cancer detection." Mr. Bellizzi has over 15 years of experience, within and beyond the Life Science industry, across operations, finance, strategic business development and investment banking. He holds an MBA from The Wharton School, a Doctorate in Dental Medicine from The University of Pennsylvania, and a Bachelor of Science degree from Georgetown University.

No comments: